A
Amelia S. George
Researcher at Vanderbilt University Medical Center
Publications - 6
Citations - 1328
Amelia S. George is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Viral load & RNA-dependent RNA polymerase. The author has an hindex of 4, co-authored 4 publications receiving 780 citations. Previous affiliations of Amelia S. George include Vanderbilt University.
Papers
More filters
Journal ArticleDOI
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Timothy P. Sheahan,Amy C. Sims,Shuntai Zhou,Rachel L. Graham,Andrea J. Pruijssers,Maria L. Agostini,Sarah R. Leist,Alexandra Schäfer,Kenneth H. Dinnon,Laura J. Stevens,James D. Chappell,Xiaotao Lu,Tia M. Hughes,Amelia S. George,Collin S. Hill,Stephanie A. Montgomery,Ariane J. Brown,Gregory R. Bluemling,Michael G. Natchus,Manohar Saindane,Alexander A. Kolykhalov,George R. Painter,Jennifer L Harcourt,Azaibi Tamin,Natalie J. Thornburg,Ronald Swanstrom,Mark R. Denison,Ralph S. Baric +27 more
TL;DR: It is shown that the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) has broad-spectrum antiviral activity against SARS- coV-2, MERS-CoV, SARS, and related zoonotic group 2b or 2c bat-CoVs, as well as increased potency against a CoV bearing resistance mutations to the nucleosid analog inhibitor remdesivir
Journal ArticleDOI
Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice.
Andrea J. Pruijssers,Andrea J. Pruijssers,Amelia S. George,Amelia S. George,Alexandra Schäfer,Sarah R. Leist,Lisa E. Gralinksi,Kenneth H. Dinnon,Boyd Yount,Maria L. Agostini,Maria L. Agostini,Laura J. Stevens,Laura J. Stevens,James D. Chappell,James D. Chappell,Xiaotao Lu,Xiaotao Lu,Tia M. Hughes,Tia M. Hughes,Kendra Gully,David R. Martinez,Ariane J. Brown,Rachel L. Graham,Jason K. Perry,Venice Du Pont,Jared Pitts,Bin Ma,Darius Babusis,Eisuke Murakami,Joy Y. Feng,John P. Bilello,Danielle P. Porter,Tomas Cihlar,Ralph S. Baric,Mark R. Denison,Mark R. Denison,Timothy P. Sheahan +36 more
TL;DR: Remdesivir (RDV) potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures and in mice infected with chimeric virus, supporting its further clinical testing for treatment of COVID-19.
Journal ArticleDOI
Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms
Laura J. Stevens,Andrea J. Pruijssers,Hery W. Lee,Calvin J. Gordon,Egor P. Tchesnokov,Jennifer L. Gribble,Amelia S. George,Tia M. Hughes,Xiaotao Lu,Jiani Li,Jason K. Perry,Danielle P. Porter,Tomas Cihlar,Timothy P. Sheahan,Ralph S. Baric,Matthias Götte,Mark R. Denison +16 more
TL;DR: The results define genetic and biochemical pathways toRDV resistance and emphasize the need for additional studies to define the potential for emergence of these or other RDV resistance mutations in clinical settings.
Posted ContentDOI
Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.
Andrea J. Pruijssers,Andrea J. Pruijssers,Amelia S. George,Amelia S. George,Alexandra Schäfer,Sarah R. Leist,Lisa E. Gralinksi,Kenneth H. Dinnon,Boyd Yount,Maria L. Agostini,Maria L. Agostini,Laura J. Stevens,Laura J. Stevens,James D. Chappell,James D. Chappell,Xiaotao Lu,Xiaotao Lu,Tia M. Hughes,Tia M. Hughes,Kendra Gully,David R. Martinez,Ariane J. Brown,Rachel L. Graham,Jason K. Perry,Venice Du Pont,Jared Pitts,Bin Ma,Darius Babusis,Eisuke Murakami,Joy Y. Feng,John P. Bilello,Danielle Porter,Tomas Cihlar,Ralph S. Baric,Mark R. Denison,Mark R. Denison,Timothy P. Sheahan +36 more
TL;DR: Remdesivir (RDV), a monophosphoramidate prodrug of an adenosine analog, potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures and supports its further clinical testing for treatment of COVID-19.
Journal ArticleDOI
Remdesivir Potently Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice
Andrea J. Pruijssers,Amelia S. George,Alexandra Schäfer,Sarah R. Leist,Lisa E. Gralinksi,Kenneth H. Dinnon,Boyd Yount,Maria L. Agostini,Laura J. Stevens,James D. Chappell,Xiaotao Lu,Tia M. Hughes,Kendra Gully,David R. Martinez,Ariane J. Brown,Rachel L. Graham,Jason K. Perry,Venice Du Pont,Jared Pitts,Bin Ma,Darius Babusis,Eisuke Murakami,Joy Y. Feng,John P. Bilello,Danielle Porter,Tomas Cihlar,Ralph S. Baric,Mark R. Denison,Timothy P. Sheahan +28 more
TL;DR: Remdesivir (RDV), a monophosphoramidate prodrug of an adenosine analog, potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures, supporting its further clinical testing for treatment of COVID-19.